U.S. markets open in 42 minutes
  • S&P Futures

    3,769.75
    +4.25 (+0.11%)
     
  • Dow Futures

    30,940.00
    +62.00 (+0.20%)
     
  • Nasdaq Futures

    12,416.25
    -38.75 (-0.31%)
     
  • Russell 2000 Futures

    2,156.00
    +11.50 (+0.54%)
     
  • Crude Oil

    65.31
    +1.48 (+2.32%)
     
  • Gold

    1,690.80
    -9.90 (-0.58%)
     
  • Silver

    25.11
    -0.35 (-1.38%)
     
  • EUR/USD

    1.1929
    -0.0050 (-0.42%)
     
  • 10-Yr Bond

    1.6200
    +0.0700 (+4.52%)
     
  • Vix

    28.19
    +1.52 (+5.70%)
     
  • GBP/USD

    1.3819
    -0.0074 (-0.54%)
     
  • USD/JPY

    108.4110
    +0.4350 (+0.40%)
     
  • BTC-USD

    48,016.00
    -1,447.83 (-2.93%)
     
  • CMC Crypto 200

    959.53
    -27.68 (-2.80%)
     
  • FTSE 100

    6,649.30
    -1.58 (-0.02%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

We're Interested To See How Vaxcyte (NASDAQ:PCVX) Uses Its Cash Hoard To Grow

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt.

So, the natural question for Vaxcyte (NASDAQ:PCVX) shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. Let's start with an examination of the business' cash, relative to its cash burn.

See our latest analysis for Vaxcyte

When Might Vaxcyte Run Out Of Money?

A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. Vaxcyte has such a small amount of debt that we'll set it aside, and focus on the US$410m in cash it held at June 2020. Looking at the last year, the company burnt through US$48m. So it had a cash runway of about 8.5 years from June 2020. Even though this is but one measure of the company's cash burn, the thought of such a long cash runway warms our bellies in a comforting way. You can see how its cash balance has changed over time in the image below.

debt-equity-history-analysis
debt-equity-history-analysis

How Is Vaxcyte's Cash Burn Changing Over Time?

Because Vaxcyte isn't currently generating revenue, we consider it an early-stage business. So while we can't look to sales to understand growth, we can look at how the cash burn is changing to understand how expenditure is trending over time. Over the last year its cash burn actually increased by 19%, which suggests that management are increasing investment in future growth, but not too quickly. However, the company's true cash runway will therefore be shorter than suggested above, if spending continues to increase. Clearly, however, the crucial factor is whether the company will grow its business going forward. So you might want to take a peek at how much the company is expected to grow in the next few years.

How Hard Would It Be For Vaxcyte To Raise More Cash For Growth?

Given its cash burn trajectory, Vaxcyte shareholders may wish to consider how easily it could raise more cash, despite its solid cash runway. Companies can raise capital through either debt or equity. One of the main advantages held by publicly listed companies is that they can sell shares to investors to raise cash and fund growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations.

Vaxcyte's cash burn of US$48m is about 2.4% of its US$2.0b market capitalisation. So it could almost certainly just borrow a little to fund another year's growth, or else easily raise the cash by issuing a few shares.

How Risky Is Vaxcyte's Cash Burn Situation?

It may already be apparent to you that we're relatively comfortable with the way Vaxcyte is burning through its cash. In particular, we think its cash runway stands out as evidence that the company is well on top of its spending. Although its increasing cash burn does give us reason for pause, the other metrics we discussed in this article form a positive picture overall. After taking into account the various metrics mentioned in this report, we're pretty comfortable with how the company is spending its cash, as it seems on track to meet its needs over the medium term. Readers need to have a sound understanding of business risks before investing in a stock, and we've spotted 2 warning signs for Vaxcyte that potential shareholders should take into account before putting money into a stock.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies insiders are buying, and this list of stocks growth stocks (according to analyst forecasts)

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.